Brii Bio Launches China’s First Domestically Developed Covid-19 Drug

Shares of Hong Kong-traded Brii Biosciences jumped to three-month high after the biotech company announced the commercial launch of China’s first domestically developed Covid-19 drug.

The amubarvimab/romlusevimab neutralizing antibody therapy was approved by China’s Medical Products Administration in December to treat adults and some children who are at high risk of developing severe Covid-19. The drug was included in China’s Covid-19 diagnosis and treatment guidelines as a recommended therapy and was added in March to the reimbursement drug list covered by the national health insurance fund.